We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Monitoring

MAVENCLAD™’S MONITORING INCLUDES PRETREATMENT SCREENING AND PERIODIC MONITORING OF LYMPHOCYTE COUNTS1

Monitoring Lymphocyte

Lymphocyte counts must be:

  • Normal before initiating MAVENCLAD in year 1
  • At least 800 cells/mm³ (i.e., Grade 0 or 1) before initiating MAVENCLAD in year 2

The treatment course in year 2 can be delayed for up to 6 months to allow for lymphocyte
recovery. If recovery takes more than 6 months, the patient should stop taking MAVENCLAD.

Should lymphocyte counts drop below 500 cells/mm³, active monitoring is recommended until values increase above 500 cells/mm³.

Screening prior to treatment initiation:

Monitoring Screening

Learn more about MAVENCLAD

 

Demonstrated efficacy

MOA

Safety and tolerability profile

 

 

Explore MAVENCLAD’s efficacy.

Learn more

Understand MAVENCLAD’s MOA.

Learn more

Learn about MAVENCLAD’s safety and
tolerability profile.

Learn more

 
Footnotes and references

MRI=magnetic resonance imaging; VZV=varicella zoster virus

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.